18.07.2025 06:06:42: Sorry, an unexpected error occurred. Please reload the page and try again..

WO2023242351 - COMBINATION THERAPY OF BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 AND BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3

National phase entry:
Publication Number WO/2023/242351
Publication Date 21.12.2023
International Application No. PCT/EP2023/066141
International Filing Date 15.06.2023
Title [English] COMBINATION THERAPY OF BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 AND BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3 [French] POLYTHÉRAPIE D'ANTICORPS BISPÉCIFIQUES DIRIGÉS CONTRE CEACAM5 ET CD47 ET ANTICORPS BISPÉCIFIQUES DIRIGÉS CONTRE CEACAM5 ET CD3
Applicants ** LAMKAP BIO BETA LTD Bahnhofstrasse 1 8808 Pfaeffikon, CH
Inventors ** BUATOIS, Vanessa 32D Chemin de la Clunaz 74270 Contamine-Sarzin, FR SECKINGER, Anja Bahnhofstrasse 1 8808 Pfaeffikon, CH HOSE, Dirk Bahnhofstrasse 1 8808 Pfaeffikon, CH
Priority Data EP22179484  16.06.2022  EP
front page image
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 1524
EPO Filing, Examination 7445
Japan Filing 556
South Korea Filing 577
USA Filing, Examination 6435
+ Add country
MasterCard Visa
Total: 16537
The term for entry into the National Phase has expired. This quotation is for informational purposes only.

QUOTE TO EMAIL ONLINE QUOTE
Abstract [English] The present invention relates to a bispecific antibody which bind to human carcinoembryonic antigen CEACAM5 and to human CD47 for use in the treatment of cancer with a bispecific antibody which bind to human carcinoembryonic antigen CEACAM5 and to human CD3ε, such combination and their use in the treatment of diseases. [French] La présente invention concerne un anticorps bispécifique qui se lie à l'antigène carcino-embryonnaire humain CEACAM5 et au CD47 humain pour une utilisation dans le traitement du cancer avec un anticorps bispécifique qui se lie à l'antigène carcino-embryonnaire humain CEACAM5 et au CD3ε humain, une telle combinaison et leur utilisation dans le traitement de maladies.